DEALS
Zhong Lun Assists Cutia Therapeutics in Listing on SEHK Main Board
Zhong Lun Assists Cutia Therapeutics in Listing on SEHK Main Board
Release time：2023-06-12
Voice Announcements
On June 12, 2023, Cutia Therapeutics (2487.HK) announced the closing of its initial public offering on the Main Board of the Stock Exchange of Hong Kong Limited, raising the net proceeds of approximately HKD 418.9 million prior to the exercise of the over-allotment option. CICC acted as the sole sponsor for the offering.
Cutia Therapeutics is an R&D driven biopharmaceutical company focused on expansive dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care and topical anesthesia. Cutia Therapeutics is principally engaged in developing innovative and comprehensive solutions that are tailored to the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market.
Zhong Lun provided legal services for Cutia Therapeutics’ incubation and inception, multiple rounds of financings and establishment of ESOP and acted as its PRC legal advisor in this offering. The legal team for the offering was led by equity partner Shaun Gao and included non-equity partner Yun Hu, associates Sally Ruan and Paul Zhou. In addition, equity partner Mark Gao and non-equity partner Ashley Hu advised on tax planning of the ESOP during its establishment.
Professionals
-
-
Ashley HU
Non-equity Partner
ShanghaiPractices： Taxation & Wealth Planning -
Ashley HU
Non-equity Partner
Shanghai
-
